Item 9A. Controls and Procedures
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to management, including our principal executive officer and principal financial officer, to allow timely decisions regarding disclosure. The Chief Executive Officer and the Chief Financial Officer have reviewed the design and effectiveness of our disclosure controls and procedures as of December 31, 2025 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.
Management’s Annual Report on Internal Control over Financial Reporting
Management of Globus is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable, but not absolute, assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. A company’s internal control over financial reporting includes those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management evaluated the internal control over financial reporting of Globus as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013) (“COSO”).
Our management has performed its assessment according to the guidelines established by the Committee of Sponsoring Organizations of the Treadway Commission. Management excluded Nevro from its assessment of internal controls over financial reporting, as it was not possible to conduct an assessment of Nevro's internal control over financial reporting in the period between the merger date and the date of management's assessment. Nevro accounted for approximately 8.5% of total assets as of December 31, 2025 and 10.0% of revenues for the year ended December 31, 2025.
Based on the foregoing and as a result of this assessment and based on the criteria in the COSO framework, management has concluded that, as of December 31, 2025, the internal control over financial reporting of Globus was effective.
Report of Independent Registered Public Accounting Firm
Deloitte & Touche LLP, our independent registered public accounting firm, has audited the effectiveness of our internal control over financial reporting as of December 31, 2025 as stated in their report that is included in Item 8 of this Form 10-K.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
103
Table of Contents
Item 9B. Other Information
Except as set forth below, during the quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).
On November 12, 2025 , Kelly G. Huller , the Company's Executive Vice President and General Counsel , adopted a trading plan intended to satisfy the condition under Rule 10b5-1(c) of the Exchange Act. Ms. Huller’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) February 7, 2027 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 67,500 shares of Class A Common pursuant to the terms of the plan.
On December 10, 2025 , David D. Davidar , a member of the Board , adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Davidar’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 36,000 shares of Class A Common pursuant to the terms of the plan.
On December 10, 2025 , Berachah Foundation (David D. Davidar's Foundation), a foundation of a member of the Board , adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. The foundation’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) December 31, 2026 or (ii) the sale of all shares subject to the plan and provides for the sale of up to 9,100 shares of Class A Common pursuant to the terms of the plan.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
104
Table of Contents
PART III
Certain information required by Part III is omitted from this Annual Report and will be included in the definitive proxy statement for our 2026 annual meeting of stockholders, which will be filed within 120 days after the end of our fiscal year.
Item 10. Directors, Executive Officers and Corporate Governance
Code of Ethics
We have adopted a Code of Ethics for all employees, officers, directors, as well as a Code of Ethics specifically for our principal executive officer and senior financial officers, both of which are available on our website, www.globusmedical.com . We intend to disclose future amendments to, or waivers from, provisions of our Code of Ethics that apply to our Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, or Controller, or persons performing similar functions, within four business days of such amendment or waiver.
Insider Trading Policy
The Company has adopted insider trading policies and procedures regarding securities transactions (the “Insider Trading Policy”) that apply to all employees, officers, directors and consultants of the Company, as well as the Company itself. The Company believes that the Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations with respect to the purchase, sale and/or other dispositions of the Company’s securities, as well as the applicable rules and regulations of the New York Stock Exchange. A copy of the Insider Trading Policy is filed as Exhibit 19 to this Annual Report on Form 10-K.
The other information required by this Item 10 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this Item 11 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item 12 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item 13 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services
The information required by this Item 14 will be set forth in the Company’s proxy statement for its 2026 annual meeting of stockholders, which information is incorporated herein by reference.
105
Table of Contents
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a) (1) Financial Statements
Reports of Independent Registered Public Accounting Firm ( Deloitte & Touche LLP , Philadelphia, Pennsylvania , PCAOB ID No. 34 )
63
Consolidated Balance Sheets
66
Consolidated Statements of Operations and Comprehensive Income
67
Consolidated Statements of Equity
68
Consolidated Statements of Cash Flows
70
Notes to Consolidated Financial Statements
72
(a) (2) Financial Statement Schedules
SCHEDULE II. VALUATION ACCOUNTS AND QUALIFYING ACCOUNTS
Allowance for doubtful accounts:
(In thousands) Beginning
of period Charged
to expenses Write-offs End
of period
Year ended December 31, 2023 $ 4,724 $ 3,658 $ 552 $ 8,934
Year ended December 31, 2024 $ 8,934 $ 16,986 $ ( 10,415 ) $ 15,505
Year ended December 31, 2025 $ 15,505 $ 10,223 $ 7,706 $ 33,434
Deferred tax valuation allowance:
Additions Deductions
(In thousands) Beginning
of period Charged
to expenses Charged to
other accounts Other
deductions End
of period
Year ended December 31, 2023 $ 5,488 $ 8,301 $ 176,974 $ — $ 190,763
Year ended December 31, 2024 $ 190,763 $ 12,825 $ ( 20,981 ) $ — $ 182,607
Year ended December 31, 2025 $ 182,607 $ ( 80,478 ) $ 37,039 $ — $ 139,168
106
Table of Contents
(b) Exhibits, including those incorporated by reference
107
Table of Contents
Exhibit No. Item
2.1 Agreement and Plan of Merger, dated as of February 8, 2023, by and among NuVasive, Inc., Globus Medical, Inc. and Zebra Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on February 9, 2023)
2.2 Agreement and Plan of Merger, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp. and Palmer Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on February 6, 2025).
3.1 Amended and Restated Certificate of Incorporation of Globus Medical, Inc. (incorporated by reference to Exhibit 3.1 of Globus Medical , Inc. ’s Amendment No. 5 to the Registration Statement on Form S-1 filed with the SEC on August 2, 2012).
3.2 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated July 30, 2012 (incorporated by reference to Exhibit 3.2 of Globus Medical, Inc. ’s Amendment No. 5 to the Registration Statement on Form S-1 filed with the SEC on August 2, 2012).
3.3 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Globus Medical, Inc., dated August 7, 2012 (incorporated by reference to Exhibit 3.1 of Globus Me dical Inc. ’s Form 10-Q/A filed with the SEC on September 19, 2012).
3.4 Amended and Restated Bylaws of Globus Medical, Inc. effective as of May 1, 2019 (incorporated by reference to Exhibit 3.1 to Globus Medical, Inc.’s Form 10-Q/A filed with the SEC on May 2, 2019).
3.5 Amendment to Bylaws effective as of July 31, 2021 (incorporated by reference to Exhibit 3.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 4, 2021).
4.1 Specimen Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 of Globus Medical Inc. ’s Amendment No. 3 to the Registration Statement on Form S-1 filed with the SEC on July 16, 2012).
4.2 Description of Securities of the Registrant (incorporated by reference to Exhibit 4.2 of Globus Medical Inc. ’s Annual Report on Form 10-K filed with the SEC on February 20, 2025).
4.3 Indenture, dated as of March 2, 2020, between NuVasive and the Trustee (incorporated by reference to Exhibit 4.1 to NuVasive, Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
4.4 First Supplemental Indenture, dated as of September 1, 2023, among Globus, NuVasive and the Trustee (incorporated by reference to Exhibit 4.2 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on September 1, 2023).
10.1 Globus Medical, Inc. 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Globus Medical Inc.’s Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
10.2 Form of Incentive Stock Option Grant Notice and Incentive Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 of Globus Medical Inc.’s Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
10.3 Form of Nonqualified Stock Option Grant Notice and Nonqualified Stock Option Agreement under 2012 Equity Incentive Plan (incorporated by reference to Exhibit 10.11 of Globus Medical Inc.’s Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
10.4 Form of Indemnification Agreement (incorporated by reference to Exhibit 10.18 of Globus Medical Inc.’s Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
10.5 Form of No Competition and Non-Disclosure Agreement (incorporated by reference to Exhibit 10.19 of Globus Medical Inc.’s Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on May 8, 2012).
10.6 Executive Employment Agreement, dated May 3, 2016 by and between Globus Medical, Inc. and Daniel T. Scavilla (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on May 4, 2016).
10.7 Executive Employment Agreement, dated August 5, 2020 by and between Globus Medical, Inc. and Kelly Huller (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 5, 2020).
10.8 Executive Employment Agreement, dated August 5, 2020 by and between Globus Medical, Inc. and Keith Pfeil (incorporated by reference to Exhibit 10.2 to Globus Medical Inc.’s Form 10-Q filed with the SEC on August 5, 2020).
10.9 Globus Medical, Inc. 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to Globus Medical Inc.’s Form 8-K filed with the SEC on June 5, 2024).
10.10 Globus Medical, Inc. 2021 Equity Incentive Plan Restricted Stock Unit Agreement (incorporated by reference to Exhibit 99.5 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.11 Globus Medical, Inc. 2021 Equity Incentive Plan Nonqualified Stock Option Agreement (incorporated by reference to Exhibit 99.6 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.12 Globus Medical, Inc. 2021 Equity Incentive Plan Restricted Stock Agreement (incorporated by reference to Exhibit 99.7 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
108
Table of Contents
10.13 Globus Medical, Inc. 2021 Equity Incentive Plan Incentive Stock Option Agreement (incorporated by reference to Exhibit 99.8 to Globus Medical Inc.’s Form S-8 filed with the SEC on December, 16, 2021).
10.14 Credit Agreement, dated as of September 27, 2023, by and among the Company, U.S. Bank National Association, as administrative agent, Citizens Bank, N.A., as syndication agent, and Royal Bank of Canada, as documentation agent, U.S. Bank National Association and Citizens Bank, N.A. as joint lead arrangers and joint book runners, and the other lenders referred to therein (incorporated by reference to Exhibit 10.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on October 2, 2023).
10.15 Guaranty, dated as of September 27, 2023, by and among U.S. Bank National Association, as administrative agent, and NuVasive, Inc., NuVasive Clinical Services Monitoring, Inc. and Branch Medical Group, as guarantors (incorporated by reference to Exhibit 10.2 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on October 2, 2023).
10.16 2014 Equity Incentive Plan (incorporated by reference to Exhibit A to NuVasive Inc.’s Definitive Proxy Statement filed with the Commission on March 27, 2014) .
10.17 2015 Ellipse Technologies, Inc. Incentive Award Plan (incorporated by reference to NuVasive Inc.’s Registration Statement on Form S-8 filed with the SEC on February 11, 2016).
10.18 Lease for Sorrento Summit, dated as of August 28, 2017, by and between HCPI/Sorrento, LLC and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on August 29, 2017).
10.19 Confirmation for base call option transaction dated as of February 26, 2020, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the with the SEC on March 2, 2020).
10.20 Confirmation for base call option transaction dated as of February 26, 2020, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.21 Confirmation for base call option transaction dated as of February 26, 2020, between Royal Bank of Canada and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.22 Confirmation for base call option transaction dated as of February 26, 2020, between The Bank of Nova Scotia and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.23 Confirmation for base call option transaction dated as of February 26, 2020, between Barclays Bank PLC and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.24 Confirmation for base warrant transaction dated as of February 26, 2020, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.25 Confirmation for base warrant transaction dated as of February 26, 2020, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.26 Confirmation for base warrant transaction dated as of February 26, 2020, between Royal Bank of Canada and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.27 Confirmation for base warrant transaction dated as of February 26, 2020, between The Bank of Nova Scotia and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.28 Confirmation for base warrant transaction dated as of February 26, 2020, between Barclays Bank PLC and the Company (incorporated by reference to NuVasive Inc.’s Current Report on Form 8-K filed with the SEC on March 2, 2020).
10.29 Bond Hedge Amendment Agreement, dated as of September 1, 2023, between Barclays Bank PLC and the Company (incorporated by reference to Exhibit 10.18 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.30 Bond Hedge Guarantee Agreement, dated as of September 1, 2023, between Barclays Bank PLC and the Company (incorporated by reference to Exhibit 10.19 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.31 Warrant Amendment Agreement, dated as of September 1, 2023, between Barclays Bank PLC and the Company (incorporated by reference to Exhibit 10.20 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.32 Warrant Guarantee Agreement, dated as of September 1, 2023, between Barclays Bank PLC and the Company (incorporated by reference to Exhibit 10.21 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
109
Table of Contents
10.33 Bond Hedge Amendment Agreement, dated as of September 1, 2023, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to Exhibit 10.22 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.34 Bond Hedge Guarantee Agreement, dated as of September 1, 2023, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to Exhibit 10.23 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.35 Warrant Amendment Agreement, dated as of September 1, 2023, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to Exhibit 10.24 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.36 Warrant Guarantee Agreement, dated as of September 1, 2023, between JPMorgan Chase Bank, National Association and the Company (incorporated by reference to Exhibit 10.25 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.37 Bond Hedge Amendment Agreement, dated as of September 1, 2023, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to Exhibit 10.26 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.38 Bond Hedge Guarantee Agreement, dated as of September 1, 2023, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to Exhibit 10.27 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.39 Warrant Amendment Agreement, dated as of September 1, 2023, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to Exhibit 10.28 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.40 Warrant Guarantee Agreement, dated as of September 1, 2023, between Morgan Stanley & Co. International plc and the Company (incorporated by reference to Exhibit 10.29 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.41 Bond Hedge Amendment Agreement, dated as of September 1, 2023, between The Bank of Nova Scotia and the Company (incorporated by reference to Exhibit 10.30 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.42 Bond Hedge Guarantee Agreement, dated as of September 1, 2023, between The Bank of Nova Scotia and the Company (incorporated by reference to Exhibit 10.31 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.43 Warrant Amendment Agreement, dated as of September 1, 2023, between The Bank of Nova Scotia and the Company (incorporated by reference to Exhibit 10.32 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.44 Warrant Guarantee Agreement, dated as of September 1, 2023, between The Bank of Nova Scotia and the Company (incorporated by reference to Exhibit 10.33 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.45 Bond Hedge Amendment Agreement, dated as of September 1, 2023, between Royal Bank of Canada and the Company (incorporated by reference to Exhibit 10.34 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.46 Bond Hedge Guarantee Agreement, dated as of September 1, 2023, between Royal Bank of Canada and the Company (incorporated by reference to Exhibit 10.35 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.47 Warrant Amendment Agreement, dated as of September 1, 2023, between Royal Bank of Canada and the Company (incorporated by reference to Exhibit 10.36 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.48 Warrant Guarantee Agreement, dated as of September 1, 2023, between Royal Bank of Canada and the Company (incorporated by reference to Exhibit 10.37 to Globus Medical, Inc.’s Current Report on Form 10-Q filed with the SEC on November 7, 2023).
10.49 Voting and Support Agreement, dated as of February 6, 2025, by and among Globus Medical, Inc., Nevro Corp., and other signatories thereto (incorporated by reference to Exhibit 10.1 to Globus Medical, Inc.’s Current Report on Form 8-K filed with the SEC on February 6, 2025).
19.1 Globus Medical, Inc. Insider Trading Policy, adopted as of February 18, 2024 (incorporated by reference to Exhibit 19.1 to Globus Medical, Inc.’s Annual Report on Form 10-K filed with the SEC on February 20, 2025).
21.1* Subsidiaries of Globus Medical, Inc.
23.1* Consent of independent registered public accounting firm – Deloitte & Touche LLP.
110
Table of Contents
31.1* Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* Certification by Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32** Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
97.1 Gl obus Compensation R ecoupment Po licy ( incor porated by reference to Exhibit 97 .1 to Globus Medical, Inc's Annual R e port o n F orm 10-K filed with the SEC on February 20, 2025).
101.INS* XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
* Filed herewith.
** Furnished herewith.
*** Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish on a supplemental basis a copy of the omitted schedules and exhibits to the Commission upon request.
Item 16. Form 10-K Summary
None.
111
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
GLOBUS MEDICAL, INC.
Dated: February 24, 2026 /s/ KEITH W. PFEIL
Keith W. Pfeil
President and Chief Executive Officer
(Principal Executive Officer)
and Director
Dated: February 24, 2026 /s/ KYLE R. KLINE
Kyle R. Kline
Chief Financial Officer
(Principal Financial Officer)
Senior Vice President
112
Table of Contents
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
SIGNATURE TITLE DATE
/s/ KEITH W. PFEIL
President and Chief Executive Officer February 24, 2026
Keith W. Pfeil
(Principal Executive Officer)
and Director
/s/ KYLE R. KLINE
Chief Financial Officer
February 24, 2026
Kyle R. Kline
(Principal Financial Officer)
Senior Vice President
/s/ DAVID C. PAUL Executive Chairman and Director February 24, 2026
David C. Paul
/s/ DAVID D. DAVIDAR Director February 24, 2026
David D. Davidar
/s/ ROBERT A. DOUGLAS
Director February 24, 2026
Robert A. Douglas
/s/ DANIEL T. LEMAITRE Director February 24, 2026
Daniel T. Lemaitre
/s/ ANN D. RHOADS Director February 24, 2026
Ann D. Rhoads
/s/ JAMES R. TOBIN Director February 24, 2026
James R. Tobin
/s/ STEPHEN T. ZARRILLI Director February 24, 2026
Stephen T. Zarrilli
/s/ JOHN A. DEFORD Director February 24, 2026
John A. DeFord
/s/ DANIEL J. WOLTERMAN Director February 24, 2026
Daniel J. Wolterman
/s/ LESLIE V. NORWALK Director February 24, 2026
Leslie V. Norwalk
113